OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.54 SEK | -2.71% |
|
+0.12% | +6.99% |
| 17/04 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
| 17/04 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
| Sales 2024 * | 617M 56.39M 4.7B | Sales 2025 * | 788M 72M 6B | Capitalization | 570M 52.08M 4.34B |
|---|---|---|---|---|---|
| Net income 2024 * | -107M -9.78M -815M | Net income 2025 * | -28M -2.56M -213M | EV / Sales 2024 * | 1.39 x |
| Net Debt 2024 * | 289M 26.42M 2.2B | Net Debt 2025 * | 201M 18.37M 1.53B | EV / Sales 2025 * | 0.98 x |
| P/E ratio 2024 * |
-5.32
x | P/E ratio 2025 * |
-19.9
x | Employees | 116 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orexo AB
More press releases
| 1 day | -2.71% | ||
| 1 week | +0.12% | ||
| Current month | +6.16% | ||
| 1 month | +11.76% | ||
| 3 months | +14.54% | ||
| 6 months | +21.44% | ||
| Current year | +6.99% |
1 week
15.58
17.54
1 month
14.8217.60
Current year
13.3217.60
1 year
8.4420.10
3 years
8.4445.40
5 years
8.4485.70
10 years
8.44149.25
| Managers | Title | Age | Since |
|---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 01/11/01 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 01/22/01 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 26/22/26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 11/19/11 | |
James Noble
CHM | Chairman | 65 | 16/20/16 |
| Director/Board Member | 62 | 01/02/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 16.54 | -2.71% | 19,414 |
| 25/24/25 | 17 | 0.00% | 8,963 |
| 24/24/24 | 17 | +2.53% | 7,316 |
| 23/24/23 | 16.58 | +5.07% | 20,373 |
| 22/24/22 | 15.78 | -4.48% | 33,396 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST
More quotes
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Sector
Pharmaceuticals
Calendar
08/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.99% | 51.97M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- ORX Stock
